These observations accentuate the immunoregulatory capability of T helper cells in this model and provide a partial explanation as to why a trial employing systemic IFN-γ treatment failed to impact disease in idiopathic pulmonary fibrosis patients [51]. The gene discussed is IFNG; the disease is idiopathic pulmonary fibrosis.